US EditionNew Keytruda and Ozempic: how China challenges the US and Europe in pharma
Summary by Eurasia Business News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
New Keytruda and Ozempic: how China challenges the US and Europe in pharma
By John Meyer, consultant in financial affairs – Eurasia Business News, July 22, 2025. Article no. 1643 China is increasingly challenging the US and Europe in pharmaceuticals, driven by rapid innovation, regulatory reforms, and demographic shifts that fuel robust growth and a surge in novel drug development. In 2025, China accounts for about 31% of the global pipeline of innovative new drugs, second only to the US at 35%, with a strong leadershi…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
